Are you currently facing challenges in antibody development, difficulty designing multi-target therapies, or complex manufacturing of non-standard formats? Our CrossMab BsIgG Generation Service helps you develop highly specific, IgG-like bispecific antibodies with superior clinical viability and high-yield manufacturing through the CrossMab/Knobs-into-Holes (KiH) platform technology with electrostatic steering modifications.
For more CrossMab BsIgG Generation or Customization details, please request a quote right now!
Bispecific antibodies (BsAbs) are engineered molecules capable of simultaneously binding two distinct antigens, offering novel mechanisms of action, such as redirecting T-cells to tumors or blocking two pathways with one agent. For instance, in oncology, CD3/CD20 T-cell engagers physically bridge immune cells to cancer cells, while in ophthalmology, dual VEGF/Ang-2 blockade targets complex disease pathways. The core challenge in manufacturing these advanced molecules lies in assembling the four different chains (two heavy chains and two light chains) without mispairing, which can result in up to ten non-functional byproducts that reduce the therapeutic yield and drastically complicate downstream purification.
The CrossMab technology solves this by strategically swapping the variable and constant domains (VL-CL or VH-CH1) in one arm. This exchange creates a specific molecular recognition site and a steric block that rigorously enforces the correct light-chain association. When combined with heavy chain heterodimerization technologies like Knobs-into-Holes (KiH), this comprehensive approach yields a stable BsIgG molecule with drug-like properties comparable to a natural IgG, fundamentally de-risking both the initial development and the eventual large-scale manufacturing.
Fig.1 Physiochemical characterization of anti-EGFR/VEGF-A CrossMab/KIH BsAb.1
Recent scientific literature strongly validates the robust engineering and therapeutic potential of the CrossMab/Knobs-into-Holes (KiH) format, particularly for challenging dual-targeting strategies. In a comprehensive study characterizing a bispecific IgG designed to inhibit both the Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor A (VEGF-A), the experiments confirmed exceptional molecular integrity. Using affinity purification and advanced analytics (SEC-HPLC, Mass Spectrometry), the research demonstrated that the CrossMab/KiH platform successfully produced a correctly assembled heterodimeric BsAb with high purity and comparable binding affinity to the individual parental monoclonal antibodies. Functionally, the study provided critical proof-of-concept in Ovarian Cancer (OC) and endothelial cell models (HUVEC). The BsAb effectively disrupted both the EGF/EGFR and VEGF-A/VEGFR2 signaling pathways, showing a clear combinatorial mode of action. Crucially, the molecule blocked paracrine angiogenic signaling driven by tumor-secreted VEGF-A.
Creative Biolabs' service is rooted in a deep understanding of antibody structure and protein engineering, delivering not just an antibody, but a molecule purpose-built for manufacturability and clinical success.
Experience the Creative Biolabs Advantage - Get a Quote Today
A: The CrossMab format's main advantage is its structural stability and superior purity profile. By combining the Knobs-into-Holes (KiH) for heavy-chain pairing with domain crossover for light-chain pairing, it virtually eliminates non-functional side products. This ensures the final product is highly homogeneous and can be purified with high yields in a robust, scalable manufacturing process, which is essential for clinical success.
A: Yes, absolutely. The CrossMab technology is highly versatile. Our service routinely generates various geometries, including the standard 1+1 BsIgG, as well as more complex 2+1 and 2+2 valencies. We can customize the format to match the exact stoichiometry and mechanism of action required for your therapeutic strategy.
A: We provide comprehensive functional QC data, including dual-target binding kinetics (KD) determined. Because the CrossMab format maintains the parental antibody's Fab region intact, the binding affinity of the BsIgG is generally preserved. We guarantee the final BsIgG will exhibit the expected dual-binding activity as confirmed by analytical assays.
A: While highly reliable, the CrossMab-VH-VL format can theoretically generate a minor Bence-Jones-like side product. At Creative Biolabs, we mitigate this by implementing orthogonal charge-pair engineering to eliminate repulsive interactions between unwanted chains, ensuring consistently high purity (≥95%). Our experts carefully select the optimal format to avoid potential byproducts specific to your molecule.
A: Due to its near-natural IgG structure and retention of the Fc region, the CrossMab format exhibits nearly identical manufacturability to a conventional mAb. This includes comparable expression yields (g/L scale), stability, and simplified downstream purification using standard Protein A chromatography. This "drug-like" property is a major cost and timeline advantage compared to non-IgG formats.
Reference
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY
SERVICES
PRODUCTS
PLATFORMS
